The Acetylcholinesterase pipeline drugs market research report outlays comprehensive information on the Acetylcholinesterase targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses the drugs in the Acetylcholinesterase pipeline by therapy areas, indications, stages, MoA, RoA, molecule type and the key players in the development pipeline. Buy the report here.
Smarter leaders trust GlobalData
The report also covers products from therapy areas such as Central Nervous System, Toxicology, Immunology, and Ophthalmology which include the indications Alzheimer’s Disease, Dementia Associated With Alzheimer’s Disease, Poisoning, Organophosphate and Carbamate Poisoning, Myasthenia Gravis, Ocular Inflammation, and Blepharitis. It also reviews key players involved in Acetylcholinesterase targeted therapeutics development with respective active and dormant or discontinued products.
The Acetylcholinesterase pipeline targets constitutes close to 63 molecules. Out of which, approximately 41 molecules are developed by companies and the remaining by the universities/institutes. The molecules developed by companies in Pre-Registration, Phase III, Phase II, Phase I, IND/ CTA Filed, Preclinical, and Discovery stages are 2, 3, 6, 14, 1, 10, and 2 respectively. Similarly, the universities portfolio in Preclinical, and Discovery comprises 12, and 10 molecule.
Acetylcholinesterase overview
Acetylcholinesterase (AChE) is an enzyme that breaks down the neurotransmitter acetylcholine (ACh). It is found in the nervous system, muscles, and red blood cells. AChE rapidly hydrolyzes the acetylcholine neurotransmitter released into the synaptic cleft, terminating the signal transduction at the neuromuscular junction.
For a complete picture of Acetylcholinesterase’s drug pipeline, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third-party sources.
Drug profiles featured in the report undergo periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
